MeiraGTx Holdings (MGTX) Metrics: History & Chart

MeiraGTx Holdings plc(MGTX)

Biotechnology · New York City, NY

$10.56-0.36 (-3.32%)

Delayed quote: Oct 6, 2026, 1:30 PM EDT

About MeiraGTx Holdings plc

MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.

New York City, NY

393 employees

www.meiragtx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Alexandria Forbes

View full financials

Third-Party DCF Estimate (FMP)	N/A
Price Gap vs Third-Party Estimate	N/A

7D Total Return	-1.71%
30D Total Return	-21.38%
YTD Total Return	+37.36%
1Y Total Return	+29.23%
3Y Total Return	+139.48%
5Y Total Return	-14.57%
10Y Total Return	N/A
15Y Total Return	N/A
20Y Total Return	N/A

2026	+37.36%
2025	+30.54%
2024	-13.25%
2023	+7.67%
2022	-72.54%
2021	+56.80%
2020

CAGR TTM	+29.07%
CAGR 3Y	+33.78%
CAGR 5Y	-3.10%
CAGR 10Y	N/A
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	15.38
PE Ratio Avg TTM	18.35
PE Ratio Avg 3Y	18.35
Current VS TTM Avg	-16.20%
Current VS 3Y Avg	-16.20%
Current VS 5Y Avg	-16.20%

All Metrics

MGTX Valuation Metrics

MGTX Stock Price Metrics

MGTX Dividend Metrics

MGTX Growth Rate Metrics

MGTX Discounted Cash Flow Metrics

MGTX Returns By Period

MGTX Yearly Returns

MGTX Average Annual Returns By Period (CAGR)

MGTX Revenue Metrics

MGTX PE Ratio Metrics

MGTX PS Ratio Metrics

MGTX PB Ratio Metrics

MGTX Price to Free Cash Flow Ratio Metrics

MGTX Debt to Equity Ratio Metrics

MGTX PEG Ratio Metrics

MGTX FCF Yield

MGTX Earnings Yield

MGTX EBITDA Yield

MGTX OCF Yield

MGTX EV/EBIT Ratio Metrics

MGTX EV/EBITDA Ratio Metrics

MGTX EV/Assets Ratio Metrics

MGTX EV/Sales Ratio Metrics

MGTX Current Ratio Metrics

MGTX Quick Ratio Metrics

MGTX ROIC Metrics

MGTX Return on Assets Metrics

MGTX Return on Equity Metrics

MGTX Net Profit Margin Metrics

MGTX Gross Profit Margin Metrics

MGTX Tax Rate Metrics

PS Ratio	2.58
PS Ratio Avg TTM	15.04
PS Ratio Avg 3Y	24.98
Current VS TTM Avg	-82.85%
Current VS 3Y Avg	-89.67%
Current VS 5Y Avg	-89.19%

PB Ratio	4.75
PB Ratio Avg TTM	106.69
PB Ratio Avg 3Y	4.36
Current VS TTM Avg	-95.55%
Current VS 3Y Avg	+8.98%
Current VS 5Y Avg	+35.97%

PFCF Ratio	46.71
PFCF Ratio Avg TTM	31.06
PFCF Ratio Avg 3Y	31.06
Current VS TTM Avg	+50.37%
Current VS 3Y Avg	+50.37%
Current VS 5Y Avg	+50.37%

Debt/Equity Ratio	0.52
Debt/Equity Ratio Avg TTM	1.74
Debt/Equity Ratio Avg 3Y	0.86
Current VS TTM Avg	-70.12%
Current VS 3Y Avg	-39.27%
Current VS 5Y Avg	-17.52%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	2.14%
FCF Yield Avg TTM	3.50%
FCF Yield Avg 3Y	3.50%
Current VS TTM Avg	-38.89%
Current VS 3Y Avg	-38.89%
Current VS 5Y Avg	-38.89%

Earnings Yield	6.50%
Earnings Yield Avg TTM	5.51%
Earnings Yield Avg 3Y	5.51%
Current VS TTM Avg	+18.01%
Current VS 3Y Avg	+18.01%
Current VS 5Y Avg	+18.01%

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	5.40
Ev/Ebit Ratio Avg TTM	6.47
Ev/Ebit Ratio Avg 3Y	6.47
Current VS TTM Avg	-16.59%
Current VS 3Y Avg	-16.59%
Current VS 5Y Avg	-16.59%

Ev/Ebitda Ratio	5.06
Ev/Ebitda Ratio Avg TTM	6.06
Ev/Ebitda Ratio Avg 3Y	6.06
Current VS TTM Avg	-16.56%
Current VS 3Y Avg	-16.56%
Current VS 5Y Avg	-16.56%

Ev/Assets Ratio	2.51
Ev/Assets Ratio Avg TTM	3.57
Ev/Assets Ratio Avg 3Y	2.22
Current VS TTM Avg	-29.74%
Current VS 3Y Avg	+13.20%
Current VS 5Y Avg	+35.45%

Ev/Sales Ratio	2.50
Ev/Sales Ratio Avg TTM	16.24
Ev/Sales Ratio Avg 3Y	22.85
Current VS TTM Avg	-84.61%
Current VS 3Y Avg	-89.06%
Current VS 5Y Avg	-88.70%

Current Ratio	3.76
Current Ratio Avg TTM	1.23
Current Ratio Avg 3Y	1.81
Current VS TTM Avg	+205.17%
Current VS 3Y Avg	+107.42%
Current VS 5Y Avg	+87.44%

Quick Ratio	3.76
Quick Ratio Avg TTM	1.23
Quick Ratio Avg 3Y	1.80
Current VS TTM Avg	+205.46%
Current VS 3Y Avg	+108.60%
Current VS 5Y Avg	+97.36%

ROIC	52.81%
ROIC Avg 3Y	(74.83%)
ROIC Avg 5Y	(59.38%)
Current VS 3Y Avg	+170.57%
Current VS 5Y Avg	+188.93%
Current VS 10Y Avg	+195.13%

ROA	19.92%
ROA Avg TTM	(3.68%)
ROA Avg 3Y	(12.59%)
Current VS TTM Avg	+641.30%
Current VS 3Y Avg	+258.23%
Current VS 5Y Avg	+277.38%

ROE	36.64%
ROE Avg TTM	N/A
ROE Avg 3Y	(140.11%)
Current VS TTM Avg	N/A
Current VS 3Y Avg	+126.15%
Current VS 5Y Avg	+148.98%

Net Profit Margin	19.87%
Net Profit Margin Avg TTM	(5821.56%)
Net Profit Margin Avg 3Y	(724.72%)
Current VS TTM Avg	+100.34%
Current VS 3Y Avg	+102.74%
Current VS 5Y Avg	+104.72%

Gross Profit Margin	97.19%
Gross Pft Margin Avg TTM	(149.18%)
Gross Pft Margin Avg 3Y	38.93%
Current VS TTM Avg	+165.15%
Current VS 3Y Avg	+149.66%
Current VS 5Y Avg	+79.88%

Tax Rate	1.45%
Tax Rate Avg 3Y	0.48%
Tax Rate Avg 5Y	0.48%
Current VS 3Y Avg	+200.00%
Current VS 5Y Avg	+200.00%
Current VS 10Y Avg	+200.00%